In-vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.
The activity of the novel, fully synthetic fluorocycline antibiotic TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates with defined carbapenem resistance mechanisms was compared against reference antimicrobials with known activity against Acinetobacter spp. The susceptibility of 323 carbapenem-resistant non-duplicate A. baumannii isolates to TP-6076, amikacin, ampicillin/sulbactam, cefepime, colistin, doxycycline, eravacycline, imipenem, levofloxacin, meropenem, minocycline, rifampin, sulbactam, tigecycline, tobramycin, and trimethoprim-sulfamethoxazole was tested using broth microdilution. TP-6076 showed greater activity than the comparators of the tetracycline class, ampicillin/sulbactam, levofloxacin, amikacin, tobramycin, trimethoprim-sulfamethoxazole, and colistin. The TP-6076 MIC50/90 values were 0.06/0.25 mg/L. Comparatively, doxycycline, eravacycline, minocycline and tigecycline MIC50/90 values were 32/>32. 0.5/1, 4/8, and 1/2 mg/L, respectively. Compared to other compounds, TP-6076 was the most active antimicrobial against carbapenem-resistant A. baumannii, including isolates that were resistant to other anti-Acinetobacter reference drugs including ampicillin/sulbactam, colistin, amikacin/tobramycin, and levofloxacin. TP-6076 is a promising new agent that may offer a useful addition to the limited armamentarium of drugs targeting this problem pathogen.